Ultragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.74), $0.22 better than the analyst estimate of ($1.96). Revenue for the quarter came in at $11.8 million versus the consensus estimate of $11.1 million.

“We’re encouraged by the growing demand for Crysvita from both children and adults with XLH in the United States, and we are making significant progress reaching doctors and helping them get patients on commercially available therapy in this early launch phase,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. “Next year, we expect to file for potential approval of our third therapy, UX007 in fatty acid oxidation disorders, and we continue to advance our two gene therapy clinical programs with additional data expected around the end of this year and in 2019.”

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.